关于肉毒神经毒素产品不可互换的最新情况
Mitchell F Brin1,2, Mariana Nelson3, Nazanin Ashourian4
1AbbVie/Allergan Aesthetics, Irvine, CA 92612, USA.
Toxins
|June 26, 2024
概括
肉毒神经毒素 (BoNT) 产品由于制造上的差异,具有独特的临床特征,因此它们不可互换. 个性化剂量和注射策略对于最佳的肉毒神经毒素治疗结果至关重要.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 肉毒神经毒素 (BoNTs) 在医疗和美学领域的使用越来越多.
- 博恩特是生物产品,其特性受到专有制造工艺的影响.
- 现有的BoNT产品具有独特的临床特性和单位强度.
研究的目的:
- 为了强调不同BoNT产品的不可互换性.
- 强调每个BoNT的个性化剂量和注射技术的重要性.
- 引导临床医生优化治疗结果,尽量减少不良事件.
主要方法:
- 审查BoNT产品的制造工艺和配方差异.
- 分析影响临床特征的因素,包括组织类型和神经内置.
- 检查影响交叉试验比较的研究设计变化.
主要成果:
- 由于独特的制造和功效测试,BoNT产品是不可互换的.
- 注射组织和神经纤维类型的差异需要特定的剂量和注射地点.
- 患者群体和试验方法的变化使跨研究的直接比较变得复杂.
结论:
- 每种肉毒神经毒素 (BoNT) 产品都有独特的临床特征,需要个性化剂量确定.
- 量身定制的注射模式对于最大化疗效,持续时间和患者满意度至关重要.
- 采用特定产品的方法将在各种医疗和美学应用中提高安全性和有效性.
关键词:
在SNAP-25中,使用SNAP-25.植物 (botulinum) 是一种植物.持续时间 持续时间免疫性 免疫性 免疫性 免疫性制造业 制造业 是一个制造业.强度强度强度是什么意思原始毒素复合体的原始毒素复合体参考标准是指参考标准的参考标准.更多相关视频
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
671
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
671
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
408
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
408
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
441
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
441
Bioequivalence: Overview
983
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
983
Depolarizing Blockers: Pharmocokinetics
317
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
317


